News
OCUL
--
0.00%
--
Ocular Therapeutix owner buys 50,000 shares worth ~$300K
Ocular Therapeutix (OCUL +3.3%) 10% owner, Summer Road LLC, bought 50,000 shares of the company in a price range of $5.78-6.45, worth ~$300K. This brings his total share holding to
Seekingalpha · 5d ago
AffaMed Therapeutics begins dosing in China trial of DEXTENZA to treat ocular inflammation
Ocular Therapeutix (OCUL -3.4%) said AffaMed Therapeutics dosed its first patient in a real-world setting study being conducted in China to evaluate the safety and efficacy of DEXTENZA (0.4 mg dexamethasone ophthalmic
Seekingalpha · 6d ago
BRIEF-Affamed Therapeutics Doses First Patient In Clinical Trial Testing Dextenza® In China In Cataract Surgery Patients
reuters.com · 6d ago
Ocular Therapeutix Announces AffaMed Therapeutics, licensee Of DEXTENZA In Certain Asian Markets, Doses Their First Patient In Clinical Trial Evaluating The Safety And Efficacy Of DEXTENZA In China In Cataract Surgery Patients
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that
Benzinga · 6d ago
AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients
BEDFORD, Mass., January 18, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that AffaMe...
Business Wire · 6d ago
Hikari Power Ltd Buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Sells ...
Tokyo, M0, based Investment company Hikari Power Ltd (Current Portfolio) buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Jack Henry & Associates Inc, Parker Hannifin Corp, sells Anheuser-Busch InBev SA/NV, The Kraft Heinz Co, Amarin C...
GuruFocus.com · 01/12 14:38
Ocular Therapeutix (NASDAQ:OCUL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Simply Wall St. · 01/04 12:44
Ocular Therapeutix trades high on director acquiring 60.9K shares
Ocular Therapeutix (OCUL +4.1%) director Summer Road, who owns 10% of the company, purchased 60.9K shares on Dec.6 at $6.02-$6.90 worth ~$380K. The transaction was carried out in two parts
Seekingalpha · 12/09/2021 17:42
FREQ, CRTO and GDEV among after hour movers
Gainers: Stitch Fix  SFIX +2%. Fate Therapeutics FATE +2%. Frequency Therapeutics (NASDAQ:FREQ) +1%. Criteo  (NASDAQ:CRTO) +1%. EVgo  EVGO +1%. Losers: Nexters  (NASDAQ:GDEV) -3%. Ocular Therapeutix (NASDAQ:OCUL) -2%. Sigilon Therapeutics  (NASDAQ:SGTX) -1...
Seekingalpha · 12/07/2021 22:00
Ocular Therapeutix's Dexamethasone Ophthalmic Insert Meets Primary Goal In Dry Eye Disease Trial
Ocular Therapeutix Inc (NASDAQ: OCUL) 
Benzinga · 12/06/2021 16:51
Ocular Therapeutix reports positive OTX-DED data in mid-stage dry eye disease study
Ocular Therapeutix (NASDAQ:OCUL) announces positive topline results from its Phase 2 clinical trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. Shares down 2.4% premarket at
Seekingalpha · 12/06/2021 14:07
BRIEF-Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease
reuters.com · 12/06/2021 12:59
Ocular Therapeutix Announces Topline Results For Phase 2 Clinical Trial Of OTX-DED For The Short-Term Treatment Of Dry Eye Disease' Co. Reports 'Study shows statistically significant improvement for primary endpoint'
Study shows statistically significant improvement for primary endpoint of bulbar conjunctival hyperemia for OTX-DED 0.2 mg (p=.004) and 0.3 mg (p=.028) formulations compared with vehicle hydrogel insert (punctal
Benzinga · 12/06/2021 12:03
Altium Capital Management LP Buys Keros Therapeutics Inc, Celldex Therapeutics Inc, X4 ...
GuruFocus News · 11/17/2021 05:49
Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences
BEDFORD, Mass., November 15, 2021--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it wi...
Business Wire · 11/15/2021 13:00
MSCI adds ZOM, CLOV, 110 others to US Micro Cap Index, MNKD, SAVA to be deleted
MSCI will be including total 112 companies  including  Zomedica (NYSE:ZOM), Clovis Oncology (NASDAQ:CLOV), 22nd Century (NASDAQ:XXII), Omeros (NASDAQ:OMER) and Verastem (NASDAQ:VSTM) in its MSCI US Micro Cap Index as a part of Semi-Annual
Seekingalpha · 11/12/2021 19:27
--Berenberg Bank Adjusts Price Target on Ocular Therapeutix to $23 From $26, Maintains Buy Rating
MT Newswires · 11/10/2021 07:58
Expert Ratings For Ocular Therapeutix
Ocular Therapeutix (NASDAQ:OCUL) has observed the following analyst ratings within the last quarter:
Benzinga · 11/09/2021 18:26
Ocular Therapeutix Stock Gains As Court Invalidates Drug Delivery Patent From Mati
Benzinga · 11/09/2021 18:17
Ocular Therapeutix Announces Success In Patent Appeal Brought By Mati Therapeutics
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the
Benzinga · 11/09/2021 14:07
Webull provides a variety of real-time OCUL stock news. You can receive the latest news about Ocular through multiple platforms. This information may help you make smarter investment decisions.
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company, which is focused on the formulation, development and commercialization of therapies for diseases and conditions of the eye using its proprietary, bioresorbable hydrogel platform technology. The Company’s product pipeline candidates provide differentiated drug delivery solutions. The Company’s products include dexamethasone insert (DEXTENZA) and ReSure Sealant. Its DEXTENZA is an intracanalicular insert for the treatment of post-surgical ocular inflammation and pain. Its ReSure Sealant is an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. The Company’s products that are in pipeline include OTX-TKI for the treatment of wet AMD, OTX-TIC for the treatment of glaucoma and ocular hypertension, OTX-CSI for the chronic treatment of dry eye disease, and OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease.